Current treatment approaches for JIA are focused on targeting the symptoms of overt inflammation, mainly through a stepwise approach with general immunosuppression by corticosteroids, methotrexate, and targeted biologics (e.g. TNF-α blockade) [3, 5]. The gene discussed is TNF; the disease is juvenile idiopathic arthritis.